These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 37170951)

  • 1. Safety profile of risankizumab in the treatment of psoriasis patients with concomitant hepatitis B or C infection: A multicentric retrospective cohort study of 49 patients.
    Ciolfi C; Balestri R; Bardazzi F; Burlando M; Chersi K; Costanzo A; Dapavo P; Gisondi P; Malagoli P; Pizzolato M; Rech G; Russo FP; Battistella S; Piaserico S
    J Eur Acad Dermatol Venereol; 2023 Oct; 37(10):e1203-e1207. PubMed ID: 37170951
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety profile of guselkumab in treatment of patients with psoriasis and coexisting hepatitis B or C: A multicenter prospective cohort study.
    Huang YH; Yen JS; Li SH; Chiu HY
    J Am Acad Dermatol; 2024 May; 90(5):1083-1086. PubMed ID: 38307145
    [No Abstract]   [Full Text] [Related]  

  • 3. Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study.
    Borroni RG; Malagoli P; Gargiulo L; Valenti M; Pavia G; Facheris P; Morenghi E; Di Corteranzo IG; Narcisi A; Ortoncelli M; Dapavo P; Costanzo A
    Acta Derm Venereol; 2021 Nov; 101(11):adv00605. PubMed ID: 34596230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risankizumab for the treatment of moderate-to-severe psoriasis: A multicenter, retrospective, 1 year real-life study.
    Caldarola G; Zangrilli A; Bernardini N; Bavetta M; De Simone C; Graceffa D; Bonifati C; Faleri S; Giordano D; Mariani M; Micheli A; Moretta G; Pagnanelli G; Panasiti V; Provini A; Richetta A; Peris K; Bianchi L
    Dermatol Ther; 2022 Jun; 35(6):e15489. PubMed ID: 35385202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
    Gordon KB; Strober B; Lebwohl M; Augustin M; Blauvelt A; Poulin Y; Papp KA; Sofen H; Puig L; Foley P; Ohtsuki M; Flack M; Geng Z; Gu Y; Valdes JM; Thompson EHZ; Bachelez H
    Lancet; 2018 Aug; 392(10148):650-661. PubMed ID: 30097359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A drug safety evaluation of risankizumab for psoriasis.
    Huang YW; Tsai TF
    Expert Opin Drug Saf; 2020 Apr; 19(4):395-402. PubMed ID: 32100591
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the SustaIMM phase 2/3 trial.
    Ohtsuki M; Fujita H; Watanabe M; Suzaki K; Flack M; Huang X; Kitamura S; Valdes J; Igarashi A
    J Dermatol; 2019 Aug; 46(8):686-694. PubMed ID: 31237727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secukinumab: A positive outcome in a patient with severe psoriasis and HBV-HCV co-infection.
    Peccerillo F; Odorici G; Pellacani G; Conti A
    Dermatol Ther; 2018 Jul; 31(4):e12601. PubMed ID: 29633448
    [No Abstract]   [Full Text] [Related]  

  • 9. Effectiveness of risankizumab in plaque psoriasis with involvement of difficult-to-treat areas: a real-world experience from two referral centers.
    Orsini D; Gargiulo L; Ibba L; Cascio Ingurgio R; Valenti M; Perugini C; Pacifico A; Maramao FS; Frascione P; Costanzo A; Narcisi A
    J Dermatolog Treat; 2023 Dec; 34(1):2220849. PubMed ID: 37288760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real world practice indirect comparison between guselkumab and risankizumab: Results from an Italian retrospective study.
    Ruggiero A; Fabbrocini G; Cinelli E; Megna M
    Dermatol Ther; 2022 Jan; 35(1):e15214. PubMed ID: 34800070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis: The UltIMMa-1 and UltIMMa-2 Randomized Clinical Trials.
    Augustin M; Lambert J; Zema C; Thompson EHZ; Yang M; Wu EQ; Garcia-Horton V; Geng Z; Valdes JM; Joshi A; Gordon KB
    JAMA Dermatol; 2020 Dec; 156(12):1344-1353. PubMed ID: 33052382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety Proļ¬le of Secukinumab in Treatment of Patients with Psoriasis and Concurrent Hepatitis B or C: A Multicentric Prospective Cohort Study.
    Chiu HY; Hui RC; Huang YH; Huang RY; Chen KL; Tsai YC; Lai PJ; Wang TS; Tsai TF
    Acta Derm Venereol; 2018 Oct; 98(9):829-834. PubMed ID: 29972221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Entecavir and intermittent etanercept therapy in a patient with concurrent hepatitis B virus infection and psoriasis.
    Babino G; Esposito M; Mazzotta A; Chimenti S; Giunta A
    Acta Derm Venereol; 2013 May; 93(3):373-4. PubMed ID: 23147755
    [No Abstract]   [Full Text] [Related]  

  • 14. Secukinumab for psoriasis in a patient with hepatitis B.
    Feaster B; Cline A; Feldman SR
    Dermatol Online J; 2018 Sep; 24(9):. PubMed ID: 30677838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risankizumab treatment in psoriasis patients who failed anti-IL17: A 52-week real-life study.
    Megna M; Potestio L; Ruggiero A; Camela E; Fabbrocini G
    Dermatol Ther; 2022 Jul; 35(7):e15524. PubMed ID: 35439341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of risankizumab in Japanese patients with generalized pustular psoriasis or erythrodermic psoriasis: Primary analysis and 180-week follow-up results from the phase 3, multicenter IMMspire study.
    Yamanaka K; Okubo Y; Yasuda I; Saito N; Messina I; Morita A
    J Dermatol; 2023 Feb; 50(2):195-202. PubMed ID: 36514850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of anti-IL-23 drugs in patients with moderate-to-severe plaque psoriasis and previous tuberculosis infection: a monocentric retrospective study.
    Ibba L; Gargiulo L; Vignoli CA; Fiorillo G; Valenti M; Costanzo A; Narcisi A
    J Dermatolog Treat; 2023 Dec; 34(1):2241585. PubMed ID: 37501617
    [No Abstract]   [Full Text] [Related]  

  • 18. [Successful treatment with risankizumab in a patient with psoriasis and HIV].
    Sanguinetti J; Suar L; Eimer L; Busso C
    Medicina (B Aires); 2022; 82(4):605-608. PubMed ID: 35904917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of Risankizumab in moderate to severe psoriasis: A systematic review and meta-analysis.
    Singh S; Singh S; Thangaswamy A; Thangaraju P; Varthya SB
    Dermatol Ther; 2021 Jan; 34(1):e14487. PubMed ID: 33140468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risankizumab in real life: preliminary results of efficacy and safety in psoriasis during a 16-week period.
    Megna M; Cinelli E; Gallo L; Camela E; Ruggiero A; Fabbrocini G
    Arch Dermatol Res; 2022 Aug; 314(6):619-623. PubMed ID: 33609180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.